In April 2025, Shapuaisi announced a profit warning, forecasting a net loss for the full year—a development that has drawn significant market attention. The company attributed the expected loss to multiple factors: on one hand, persistent weakness in demand for its core product, Shapuaisi eye drops, compounded by external pressures such as national healthcare cost controls and centralized drug procurement policies, has led to a sharp decline in sales revenue. On the other hand, increased investment in new drug R&D and business transformation has yet to yield meaningful returns in the short term, further squeezing profit margins. Additionally, intensifying competition in the ophthalmic pharmaceutical market and the emergence of alternative products have challenged Shapuaisi’s traditional competitive edge. In response, the company is actively pursuing a diversified strategy, including expanding its OTC distribution channels, developing functional eye health products, and exploring international collaborations. Despite near-term headwinds, management expressed confidence in its long-term prospects, aiming to restore profitability through product innovation and structural optimization. Investors should closely monitor upcoming financial reports and the effectiveness of its strategic initiatives.
2025年4月，莎普爱思（Shapuaisi）发布业绩预告，预计全年将出现净亏损。这一消息引发市场广泛关注。公司表示，亏损主要受多重因素影响：一方面，核心产品——莎普爱思滴眼液的市场需求持续疲软，叠加医保控费、集采政策等外部压力，导致销售收入显著下滑；另一方面，公司在新药研发及业务转型方面投入加大，短期内尚未形成有效收益，进一步压缩了利润空间。此外，近年来眼科用药市场竞争加剧，同类替代产品不断涌现，也对莎普爱思的传统优势构成挑战。为应对困境，公司正积极布局多元化战略，包括拓展OTC渠道、探索功能性眼健康产品以及推进国际化合作。尽管短期承压，管理层仍强调长期发展信心，希望通过产品创新与结构优化逐步恢复盈利能力。投资者需密切关注其后续财报披露及战略执行成效。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/13071.html